There are about 400 million patients of hepatitis in the world. Some of them are suffering from autoimmune hepatitis, a disease in which the body's immune system attacks liver cells.
A research team headed by Prof. TIAN Zhigang from the University of Science and Technology of China (USTC) recently discovered that a cytokine, a protein produced by white blood cells that act as chemical messengers between cells, could prevent mice liver from immune-mediated injury. The work, which was published at the recent issue of prestigious journal HEPATOLOGY, is applauded as providing guidance for the treatment of human autoimmune hepatitis.
Con-A-induced hepatitis is considered a good experimental model of human autoimmune hepatitis with characterized by leukocyte activation and infiltration of the liver. Using the model, Prof. Tian and colleagues found that injection of Interleukin-15 (IL-15), an important cytokine, could prevent mice from Con A-induced mortality, elevation of serum transaminase, liver necrosis, and hepatocyte apoptosis.
The researchers discovered that the mechanism for this lies in the fact that IL-15 pretreatment could decrease the NKT-derived IL-4, IL-5, and TNF- production, thereby resulting in less infiltration of eosinophils, which play a critical role in Con A-induced liver injury. Their studies indicate that IL-15 protects against Con A-induced liver injury via an NKT cell-dependent mechanism by reducing their production of IL-4, IL-5, and infiltration of eosinophils. These findings suggest that IL-15 may be of therapeutic relevance in human autoimmune-related hepatitis.
Tuesday, April 14, 2009
Monday, April 13, 2009
No Cancer! I got Vaccinated
FOR TWITTERS http://bit.ly/hnpzR
According to CBDM.T®, the market and business intelligence company, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. The vaccine market could account for more than 25 billion by 2012.
Paris, France (PRWEB) April 13, 2009 -- Vaccines are substances used to stimulate the production of antibodies and provide immunity against one or several diseases. The vaccination was first used by Edward Jenner in 1796 against smallpox and furthered by Louis Pasteur in the 1870's. Vaccines are developed from whole dead or attenuated organisms, pathogen protein toxin (toxoids), pathogen surface molecules, inactivated or attenuated virus and more recently from DNA plasmid carrying an antigen-coding gene.
According to CBDM.T, vaccines represent one of the fastest growing pharmaceutical product categories at over 17% per annum to 2012. This is driven largely by strong growth of HPV vaccines (Human Papilloma Virus,Cervarix and Gardasil), paediatric vaccines (Rotarix) launched into developing markets and meningitis vaccines (Prevnar, Menactra), the successful life cycle management of combination vaccines such as Pentacel and Infanrix, and expansion of the flu market. Childhood vaccines are the main segment, accounting for around 56% of the global vaccine market.
In 2008, 220 vaccines were under development from discovery (84 products), preclinical (39 products), clinical phase 1 (36 products), clinical phase 2 (50 products) to clinical phase 3 (with 14 products). 17 products were on the market. The leading top 5 pharmaceutical companies in this market are Sanofi-Aventis, GSK, Wyeth, Merck and Novartis (Chiron).
Vaccines are big business. According to CBDM.T®, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. USA sales account for 45% of total '/>"/>
Source: PRWebCopyright©2009 Vocus, Inc.All rights reserved
According to CBDM.T®, the market and business intelligence company, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. The vaccine market could account for more than 25 billion by 2012.
Paris, France (PRWEB) April 13, 2009 -- Vaccines are substances used to stimulate the production of antibodies and provide immunity against one or several diseases. The vaccination was first used by Edward Jenner in 1796 against smallpox and furthered by Louis Pasteur in the 1870's. Vaccines are developed from whole dead or attenuated organisms, pathogen protein toxin (toxoids), pathogen surface molecules, inactivated or attenuated virus and more recently from DNA plasmid carrying an antigen-coding gene.
According to CBDM.T, vaccines represent one of the fastest growing pharmaceutical product categories at over 17% per annum to 2012. This is driven largely by strong growth of HPV vaccines (Human Papilloma Virus,Cervarix and Gardasil), paediatric vaccines (Rotarix) launched into developing markets and meningitis vaccines (Prevnar, Menactra), the successful life cycle management of combination vaccines such as Pentacel and Infanrix, and expansion of the flu market. Childhood vaccines are the main segment, accounting for around 56% of the global vaccine market.
In 2008, 220 vaccines were under development from discovery (84 products), preclinical (39 products), clinical phase 1 (36 products), clinical phase 2 (50 products) to clinical phase 3 (with 14 products). 17 products were on the market. The leading top 5 pharmaceutical companies in this market are Sanofi-Aventis, GSK, Wyeth, Merck and Novartis (Chiron).
Vaccines are big business. According to CBDM.T®, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. USA sales account for 45% of total '/>"/>
Source: PRWebCopyright©2009 Vocus, Inc.All rights reserved
No Cancer! I avoided carcinogens and I got Vaccinated
OP ED-COMMENTARY
The following is the opinion of this writer only Alonzo Peters MD , and not TDB, or Brain Activity or Right Brain Activity.
If you can avoid cancer, would you, if it meant a dietary, and exercise-lifestyle change, including avoidance of unprotected sex (HPV/HIV) and alcoholic beverages? The researchers are betting no.
Or, would you continue to opt for no change in hopes that vaccines and other " new research " would come up with cures? It depends on whether you have cancer or not! It also depends on who the PAYOR IS ! Nevertheless there will be 16 billion predominantly on avoidance of cancer
in lieu of the possibility of exposure to a known cancer initiator- viral or otherwise.
The current British debate is whether new cures should be parceled out under a socialist system and who should get them to improve quantity and quality of life.
The greedy international reseachers and initial "investors" are quick to try to jack a price of the drug up in hopes that the US government will subsidize them with VA, Medicare and Medicaid funding. Mexico and other countries get UP TO 1/2 prices as negotiated. This is irregardless of whether the technology is based on sound science or not. If it does not mention the Kreb or Urea cycles, cytokines , HuR receptors ,inflammation you might as well forget it . It is a scam! The Human Genome Project as well as Stem Cell research is for naught until the Cytokine Cycle is introduced as priority and then tested in vitro
FOR TWITTERS http://bit.ly/hnpzR
According to CBDM.T®, the market and business intelligence company, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. The vaccine market could account for more than 25 billion by 2012.
Paris, France (PRWEB) April 13, 2009 -- Vaccines are substances used to stimulate the production of antibodies and provide immunity against one or several diseases. The vaccination was first used by Edward Jenner in 1796 against smallpox and furthered by Louis Pasteur in the 1870's. Vaccines are developed from whole dead or attenuated organisms, pathogen protein toxin (toxoids), pathogen surface molecules, inactivated or attenuated virus and more recently from DNA plasmid carrying an antigen-coding gene.
According to CBDM.T, vaccines represent one of the fastest growing pharmaceutical product categories at over 17% per annum to 2012. This is driven largely by strong growth of HPV vaccines (Human Papilloma Virus,Cervarix and Gardasil), paediatric vaccines (Rotarix) launched into developing markets and meningitis vaccines (Prevnar, Menactra), the successful life cycle management of combination vaccines such as Pentacel and Infanrix, and expansion of the flu market. Childhood vaccines are the main segment, accounting for around 56% of the global vaccine market.
In 2008, 220 vaccines were under development from discovery (84 products), preclinical (39 products), clinical phase 1 (36 products), clinical phase 2 (50 products) to clinical phase 3 (with 14 products). 17 products were on the market. The leading top 5 pharmaceutical companies in this market are Sanofi-Aventis, GSK, Wyeth, Merck and Novartis (Chiron).
Vaccines are big business. According to CBDM.T®, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. USA sales account for 45% of total '/>"/>
Source: PRWebCopyright©2009 Vocus, Inc.All rights reserved
The following is the opinion of this writer only Alonzo Peters MD , and not TDB, or Brain Activity or Right Brain Activity.
If you can avoid cancer, would you, if it meant a dietary, and exercise-lifestyle change, including avoidance of unprotected sex (HPV/HIV) and alcoholic beverages? The researchers are betting no.
Or, would you continue to opt for no change in hopes that vaccines and other " new research " would come up with cures? It depends on whether you have cancer or not! It also depends on who the PAYOR IS ! Nevertheless there will be 16 billion predominantly on avoidance of cancer
in lieu of the possibility of exposure to a known cancer initiator- viral or otherwise.
The current British debate is whether new cures should be parceled out under a socialist system and who should get them to improve quantity and quality of life.
The greedy international reseachers and initial "investors" are quick to try to jack a price of the drug up in hopes that the US government will subsidize them with VA, Medicare and Medicaid funding. Mexico and other countries get UP TO 1/2 prices as negotiated. This is irregardless of whether the technology is based on sound science or not. If it does not mention the Kreb or Urea cycles, cytokines , HuR receptors ,inflammation you might as well forget it . It is a scam! The Human Genome Project as well as Stem Cell research is for naught until the Cytokine Cycle is introduced as priority and then tested in vitro
FOR TWITTERS http://bit.ly/hnpzR
According to CBDM.T®, the market and business intelligence company, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. The vaccine market could account for more than 25 billion by 2012.
Paris, France (PRWEB) April 13, 2009 -- Vaccines are substances used to stimulate the production of antibodies and provide immunity against one or several diseases. The vaccination was first used by Edward Jenner in 1796 against smallpox and furthered by Louis Pasteur in the 1870's. Vaccines are developed from whole dead or attenuated organisms, pathogen protein toxin (toxoids), pathogen surface molecules, inactivated or attenuated virus and more recently from DNA plasmid carrying an antigen-coding gene.
According to CBDM.T, vaccines represent one of the fastest growing pharmaceutical product categories at over 17% per annum to 2012. This is driven largely by strong growth of HPV vaccines (Human Papilloma Virus,Cervarix and Gardasil), paediatric vaccines (Rotarix) launched into developing markets and meningitis vaccines (Prevnar, Menactra), the successful life cycle management of combination vaccines such as Pentacel and Infanrix, and expansion of the flu market. Childhood vaccines are the main segment, accounting for around 56% of the global vaccine market.
In 2008, 220 vaccines were under development from discovery (84 products), preclinical (39 products), clinical phase 1 (36 products), clinical phase 2 (50 products) to clinical phase 3 (with 14 products). 17 products were on the market. The leading top 5 pharmaceutical companies in this market are Sanofi-Aventis, GSK, Wyeth, Merck and Novartis (Chiron).
Vaccines are big business. According to CBDM.T®, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. USA sales account for 45% of total '/>"/>
Source: PRWebCopyright©2009 Vocus, Inc.All rights reserved
Saturday, April 11, 2009
Tid bits. I mean TWIT BITS
Huntington's Chorea
Twit Bit-
http://bit.ly/qLlOj
Howard Hughes Medical Institute researchers have designed tiny RNA molecules that shut off the gene that causes Huntington's disease without damaging that gene's healthy counterpart, which maintains the health and vitality of neurons. Laboratory studies suggest that a single small interfering RNA could reduce production of the damaging Huntingtin protein in nearly half of people with the disease. Another 25 percent of patients might benefit from one of a set of four additional small interfering RNAs.
Phillip D. Zamore, an HHMI investigator at the University of Massachusetts Medical School in Worcester, and his colleagues reported their findings in an article published April 9, 2009, in the journal Current Biology.
There is no treatment for Huntington's disease, which is caused by a mutant form of the Huntingtin gene. Huntingtin is required for healthy nerve cells, but the mutant gene makes a toxic protein that contains excess amounts of the amino acid glutamine.
The key to whether the Huntingtin gene is normal or defective lies in a kind of genetic stutter: a repetitive sequence of the DNA triplet CAG, which codes for the amino acid glutamine. Stretches of CAG "repeats" appear in every human being's Huntingtin gene, but the length varies. Whereas the normal gene has a sequence of between six and 34 CAG repeats, the abnormal gene contains many more. In fact, any stretch of DNA containing more than 40 of these repeats ensures that its bearer will develop Huntington'sthe greater the number of repeats, the earlier the disease strikes and the greater its ferocity. The abnormal Huntingtin protein causes movement disorders, cognitive failure, and ultimately, death. Children who have a parent with Huntington's disease have a 50 percent chance of inheriting the disease themselves.
Zamore studies how RNA interference can be used to silence genes selectively. In the 1990s, he and other scientists
Contact: Jennifer Michalowski
mailto:Michalowskimichalow@hhmi.org
301-215-8576
Howard Hughes Medical InstituteSource:Eurekalert
On Globlastomas
Could Antineoplastins work the same way?
Twit BIT-
http://bit.ly/1IYCC
CHAPEL HILL Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how a particular gene mutation contributes to tumor growth.
The findings and potential treatment apply to a type of brain tumor called secondary glioblastoma multiforme (GBM). GBMs are part of a larger group of brain tumors called malignant gliomas, which is the type of cancer Senator Edward Kennedy suffers from.
A report of the research will appear in the April 10, 2009 issue of the journal Science. In experiments with tumor cells, the researchers reversed the effects of a mutation in a gene called isocitrate dehydrogenase-1 (IDH1) by replenishing a compound called α-ketoglutarate (α-KG).
"When the IDH1 gene is mutated, the level of α-KG is reduced, which in turn contributes to tumor growth by helping to increase the supply of nutrients and oxygen to tumor cells. When we added the α-KG to tumor cells, the effects caused by the IDH1 mutation were reversed," said Yue Xiong, Ph.D., William R. Kenan Jr., Distinguished Professor of Biochemistry and Biophysics and a member of the UNC Lineberger Comprehensive Cancer Center.
"If scientists can develop α-KG into a clinical drug, it could potentially be used for treating brain tumor patients who have this specific gene mutation. The α-KG compound is already there; it only needs to be modified to be used clinically, so that may save a lot of time," Xiong said.
Xiong is a corresponding author of the study along with Kun-Liang Guan, Ph.D., professor of pharmacology at the University of California, San Diego. The findings and potential treatment apply mostly to secondary GBM, rather than a different type of tumor called primary GBM. About 75 percent of secondary GBMs have mutations in the IDH1 gene, but only 5 percent of primary GBMs
Contact: Dianne Shawdgs@med.unc.edu919-966-7834University of North Carolina School of MedicineSource:Eurekalert
On Cloud computing of protein ressearh
Twit bit -
http://bit.ly/tOmf
Researchers at the Medical College of Wisconsin Biotechnology and Bioengineering Center in Milwaukee have just made the very expensive and promising area of protein research more accessible to scientists worldwide.
They have developed a set of free tools called ViPDAC (virtual proteomics data analysis cluster), to be used in combination with Amazon's inexpensive "cloud computing" service, which provides the option to rent processing time on its powerful servers; and free open-source software from the National Institutes of Health (NIH) and the University of Manitoba.
Their research appears online in Journal of Proteomic Research and is funded by the NIH Heart Lung and Blood Institute's Proteomics Innovation Center at the Medical College. Proteomics is a biomedical research term used to describe the large-scale study of all the proteins expressed by an organism. It usually involves the identification of proteins and determination of their modifications in both normal and disease states.
One of the major challenges for many laboratories setting up proteomics programs has been obtaining and maintaining the very costly computational infrastructure required for analysis of the vast flow of proteomics data generated by mass spectrometry instruments used to determine the elemental composition as well as chemical structure of a molecule, according to senior investigator, Simon Twigger, Ph.D., assistant professor of physiology.
"We're applying this technology in our Proteomics Center to study cardiovascular disease, the effects of radiation damage, and in our collaboration with the University of Wisconsin- Madison stem cell research group," he says.
With cloud computing making the analysis less expensive and more accessible, many more users can set up and customize their own systems. Investigators can analyze their data in greater depth than previously possible, making it possible for them to learn more about t'/>"/>
Contact: Eileen La Susalasusa@mcw.edu414-456-4700Medical College of WisconsinSource:Eurekalert
ON Protein Increase in PLANTS for FOOD
For my Twitters - http://bit.ly/KTcME
RIVERSIDE, Calif. The small flowering plant Arabidopsis is widely used in laboratories as a model organism in plant biology.
A member of the mustard family, Arabidopsis offers researchers several advantages such as a completely sequenced genome, a compact size, a life-cycle of about only six weeks from seed to seed, easy cultivation and high seed production.
Now Daniel Gallie, a professor of biochemistry at UC Riverside, has received a three-year grant of nearly $1.75 million from the National Science Foundation to study how each Arabidopsis gene is converted into protein and how plants control this process.
The research can help improve protein production in crops. Protein-rich crops improve the diet of humans directly and promote livestock productivity for a growing world population. Besides their nutritional advantages, these crops also reduce the environmental impact of livestock production by potentially reducing the acreage required for agriculture.
"Understanding how most genes, out of the more than 25,000 genes in Arabidopsis, are converted into protein will be important in understanding how plants control protein synthesis," Gallie said. "This knowledge is essential in improving protein production in crops."
With the advent of the complete sequence of the genome of Arabidopsis and other plant species, researchers are now in a position of being able to understand how every gene in an organism is converted into protein.
"This, in conjunction with the development of other recent technologies, such as the ability to identify mutants in most genes as well as to analyze virtually all genes in Arabidopsis on a chip no larger than a fingertip, makes such a study possible for the first time," Gallie said.
He explained that the process of protein producti'/>"/>
Contact: Iqbal Pittalwalaiqbal@ucr.edu951-827-6050University of California - RiversideSource:Eurekalert
On Information transfer
URL- http://www.youtube.com/watch?v=VQ3d3KigPQM
Bit - http://bit.ly/1AbtCW
On Dancing
URL - http://www.youtube.com/watch?v=cL9Wu2kWwSY
Bit- http://bit.ly/MbliY
I love you! I love you in Jesus name and there is nothing that you can do about it!
Twit Bit-
http://bit.ly/qLlOj
Howard Hughes Medical Institute researchers have designed tiny RNA molecules that shut off the gene that causes Huntington's disease without damaging that gene's healthy counterpart, which maintains the health and vitality of neurons. Laboratory studies suggest that a single small interfering RNA could reduce production of the damaging Huntingtin protein in nearly half of people with the disease. Another 25 percent of patients might benefit from one of a set of four additional small interfering RNAs.
Phillip D. Zamore, an HHMI investigator at the University of Massachusetts Medical School in Worcester, and his colleagues reported their findings in an article published April 9, 2009, in the journal Current Biology.
There is no treatment for Huntington's disease, which is caused by a mutant form of the Huntingtin gene. Huntingtin is required for healthy nerve cells, but the mutant gene makes a toxic protein that contains excess amounts of the amino acid glutamine.
The key to whether the Huntingtin gene is normal or defective lies in a kind of genetic stutter: a repetitive sequence of the DNA triplet CAG, which codes for the amino acid glutamine. Stretches of CAG "repeats" appear in every human being's Huntingtin gene, but the length varies. Whereas the normal gene has a sequence of between six and 34 CAG repeats, the abnormal gene contains many more. In fact, any stretch of DNA containing more than 40 of these repeats ensures that its bearer will develop Huntington'sthe greater the number of repeats, the earlier the disease strikes and the greater its ferocity. The abnormal Huntingtin protein causes movement disorders, cognitive failure, and ultimately, death. Children who have a parent with Huntington's disease have a 50 percent chance of inheriting the disease themselves.
Zamore studies how RNA interference can be used to silence genes selectively. In the 1990s, he and other scientists
Contact: Jennifer Michalowski
mailto:Michalowskimichalow@hhmi.org
301-215-8576
Howard Hughes Medical InstituteSource:Eurekalert
On Globlastomas
Could Antineoplastins work the same way?
Twit BIT-
http://bit.ly/1IYCC
CHAPEL HILL Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how a particular gene mutation contributes to tumor growth.
The findings and potential treatment apply to a type of brain tumor called secondary glioblastoma multiforme (GBM). GBMs are part of a larger group of brain tumors called malignant gliomas, which is the type of cancer Senator Edward Kennedy suffers from.
A report of the research will appear in the April 10, 2009 issue of the journal Science. In experiments with tumor cells, the researchers reversed the effects of a mutation in a gene called isocitrate dehydrogenase-1 (IDH1) by replenishing a compound called α-ketoglutarate (α-KG).
"When the IDH1 gene is mutated, the level of α-KG is reduced, which in turn contributes to tumor growth by helping to increase the supply of nutrients and oxygen to tumor cells. When we added the α-KG to tumor cells, the effects caused by the IDH1 mutation were reversed," said Yue Xiong, Ph.D., William R. Kenan Jr., Distinguished Professor of Biochemistry and Biophysics and a member of the UNC Lineberger Comprehensive Cancer Center.
"If scientists can develop α-KG into a clinical drug, it could potentially be used for treating brain tumor patients who have this specific gene mutation. The α-KG compound is already there; it only needs to be modified to be used clinically, so that may save a lot of time," Xiong said.
Xiong is a corresponding author of the study along with Kun-Liang Guan, Ph.D., professor of pharmacology at the University of California, San Diego. The findings and potential treatment apply mostly to secondary GBM, rather than a different type of tumor called primary GBM. About 75 percent of secondary GBMs have mutations in the IDH1 gene, but only 5 percent of primary GBMs
Contact: Dianne Shawdgs@med.unc.edu919-966-7834University of North Carolina School of MedicineSource:Eurekalert
On Cloud computing of protein ressearh
Twit bit -
http://bit.ly/tOmf
Researchers at the Medical College of Wisconsin Biotechnology and Bioengineering Center in Milwaukee have just made the very expensive and promising area of protein research more accessible to scientists worldwide.
They have developed a set of free tools called ViPDAC (virtual proteomics data analysis cluster), to be used in combination with Amazon's inexpensive "cloud computing" service, which provides the option to rent processing time on its powerful servers; and free open-source software from the National Institutes of Health (NIH) and the University of Manitoba.
Their research appears online in Journal of Proteomic Research and is funded by the NIH Heart Lung and Blood Institute's Proteomics Innovation Center at the Medical College. Proteomics is a biomedical research term used to describe the large-scale study of all the proteins expressed by an organism. It usually involves the identification of proteins and determination of their modifications in both normal and disease states.
One of the major challenges for many laboratories setting up proteomics programs has been obtaining and maintaining the very costly computational infrastructure required for analysis of the vast flow of proteomics data generated by mass spectrometry instruments used to determine the elemental composition as well as chemical structure of a molecule, according to senior investigator, Simon Twigger, Ph.D., assistant professor of physiology.
"We're applying this technology in our Proteomics Center to study cardiovascular disease, the effects of radiation damage, and in our collaboration with the University of Wisconsin- Madison stem cell research group," he says.
With cloud computing making the analysis less expensive and more accessible, many more users can set up and customize their own systems. Investigators can analyze their data in greater depth than previously possible, making it possible for them to learn more about t'/>"/>
Contact: Eileen La Susalasusa@mcw.edu414-456-4700Medical College of WisconsinSource:Eurekalert
ON Protein Increase in PLANTS for FOOD
For my Twitters - http://bit.ly/KTcME
RIVERSIDE, Calif. The small flowering plant Arabidopsis is widely used in laboratories as a model organism in plant biology.
A member of the mustard family, Arabidopsis offers researchers several advantages such as a completely sequenced genome, a compact size, a life-cycle of about only six weeks from seed to seed, easy cultivation and high seed production.
Now Daniel Gallie, a professor of biochemistry at UC Riverside, has received a three-year grant of nearly $1.75 million from the National Science Foundation to study how each Arabidopsis gene is converted into protein and how plants control this process.
The research can help improve protein production in crops. Protein-rich crops improve the diet of humans directly and promote livestock productivity for a growing world population. Besides their nutritional advantages, these crops also reduce the environmental impact of livestock production by potentially reducing the acreage required for agriculture.
"Understanding how most genes, out of the more than 25,000 genes in Arabidopsis, are converted into protein will be important in understanding how plants control protein synthesis," Gallie said. "This knowledge is essential in improving protein production in crops."
With the advent of the complete sequence of the genome of Arabidopsis and other plant species, researchers are now in a position of being able to understand how every gene in an organism is converted into protein.
"This, in conjunction with the development of other recent technologies, such as the ability to identify mutants in most genes as well as to analyze virtually all genes in Arabidopsis on a chip no larger than a fingertip, makes such a study possible for the first time," Gallie said.
He explained that the process of protein producti'/>"/>
Contact: Iqbal Pittalwalaiqbal@ucr.edu951-827-6050University of California - RiversideSource:Eurekalert
On Information transfer
URL- http://www.youtube.com/watch?v=VQ3d3KigPQM
Bit - http://bit.ly/1AbtCW
On Dancing
URL - http://www.youtube.com/watch?v=cL9Wu2kWwSY
Bit- http://bit.ly/MbliY
I love you! I love you in Jesus name and there is nothing that you can do about it!
Tuesday, April 7, 2009
4-7-9 PM
http://bit.ly/oMBf -for Twitterites
HOUSTON, April 7 /PRNewswire/ -- SeqWright Inc., an international leader in the field of contract genomic services, announced today its involvement in Hologic's (formerly Third Wave Technologies) successful clinical trials of two Human Papillomavirus (HPV) in vitro diagnostic tests. SeqWright provided FDA submission quality DNA sequencing of multiple HPV strains and bioinformatics support to validate two Hologic HPV diagnostic tests; Cervista HPV High Risk (HR) and Cervista HPV 16/18, in preparation for FDA submission. Both tests were recently awarded FDA premarket approval. According to Hologic, their Cervista HPV HR clinical trial involved over 4,000 women spread across 89 sites throughout the United States and constituted one of the largest and most demographically diverse clinical trials ever conducted in the United States.
SeqWright was selected to perform the sequencing-based validations of Hologic's HPV Diagnostics assays after successfully completing several of Hologic's previous clinical trials, which all led to FDA approvals. SeqWright maintains advanced quality control with a Clinical Laboratory Improvement Amendment (CLIA) certification as well as maintaining compliance with Good Laboratory Practices (GLPs) as specified in the Code of Federal Regulations.
Sequencing for Hologic's clinical trials was performed under GLP guidelines (4X-bidirectional sequencing, stringent controls, full documentation) and all samples were continuously tracked and monitored. The bioinformatics provided by SeqWright were also vital to trial success and were used to implement Hologic's HPV genotyping analysis as well as to create a customized clinical trial decision tree algorithm. These services led to a streamlined, reliable and efficient testing regimen in support of Hologic's two recently approved HPV Diagnostics.
SeqWright CEO, Dr. Fei Lu, M.D. stated, "We wish to congratulate Hologic on the '/>"/> pre-market approvals of their new HPV diagnostic tests and we are proud of the work we performed in support of their efforts."
About SeqWright:
SeqWright Incorporated is a world-class genomic services support organization based in Houston, TX with more than fifteen years of experience specializing in state of the art Molecular Biology and Genomic services within a highly regulated GLP/CLIA environment. For additional information about SeqWright and its services, please visit www.seqwright.com.
SOURCE SeqWright Inc.Copyright©2009 PR Newswire.All rights reserved
HOUSTON, April 7 /PRNewswire/ -- SeqWright Inc., an international leader in the field of contract genomic services, announced today its involvement in Hologic's (formerly Third Wave Technologies) successful clinical trials of two Human Papillomavirus (HPV) in vitro diagnostic tests. SeqWright provided FDA submission quality DNA sequencing of multiple HPV strains and bioinformatics support to validate two Hologic HPV diagnostic tests; Cervista HPV High Risk (HR) and Cervista HPV 16/18, in preparation for FDA submission. Both tests were recently awarded FDA premarket approval. According to Hologic, their Cervista HPV HR clinical trial involved over 4,000 women spread across 89 sites throughout the United States and constituted one of the largest and most demographically diverse clinical trials ever conducted in the United States.
SeqWright was selected to perform the sequencing-based validations of Hologic's HPV Diagnostics assays after successfully completing several of Hologic's previous clinical trials, which all led to FDA approvals. SeqWright maintains advanced quality control with a Clinical Laboratory Improvement Amendment (CLIA) certification as well as maintaining compliance with Good Laboratory Practices (GLPs) as specified in the Code of Federal Regulations.
Sequencing for Hologic's clinical trials was performed under GLP guidelines (4X-bidirectional sequencing, stringent controls, full documentation) and all samples were continuously tracked and monitored. The bioinformatics provided by SeqWright were also vital to trial success and were used to implement Hologic's HPV genotyping analysis as well as to create a customized clinical trial decision tree algorithm. These services led to a streamlined, reliable and efficient testing regimen in support of Hologic's two recently approved HPV Diagnostics.
SeqWright CEO, Dr. Fei Lu, M.D. stated, "We wish to congratulate Hologic on the '/>"/> pre-market approvals of their new HPV diagnostic tests and we are proud of the work we performed in support of their efforts."
About SeqWright:
SeqWright Incorporated is a world-class genomic services support organization based in Houston, TX with more than fifteen years of experience specializing in state of the art Molecular Biology and Genomic services within a highly regulated GLP/CLIA environment. For additional information about SeqWright and its services, please visit www.seqwright.com.
SOURCE SeqWright Inc.Copyright©2009 PR Newswire.All rights reserved
4-7-9 Updates
http://bit.ly/puPdu Sprint commercial but good perspective on twitter and integration
visualization example: http://tinyurl.com/d8yr3t it mentions twitter too (via @canuckflack)
http://blog.searchenginewatch.com/090407-140506 - page view increase with spokesperson
http://bit.ly/UFDx3
http://www.itbusinessedge.com/cm/blogs/weinschenk/the-status-of-electronic-health-care-upgraded-to-probable/?cs=31655
medical electronic care
10 signs of needing a life http://www.minervity.com/?p=2392
RT franchiselookup . The name speaks growth
Opportunity for SL http://www.bio-medicine.org/biology-technology-1/Ansell-Healthcare-Espresses-Firm-Commitment-to-Support-Continued-Education-of-Healthcare-Professionals-Worldwide-11417-1/
http://bit.ly/iehnq
BRUSSELS, April 7 /PRNewswire/ --
- European Operating Room Nurses Association (EORNA) to Confirm AnsellCares(R), the Ansell Global Healthcare Educational Program, Accepted for Accreditation
Earlier today, Ansell Healthcare, the global leader in healthcare barrier protective solutions, has announced it has taken a further step in supporting the global healthcare professionals community in the area of continued education.
After receiving earlier confirmation of acceptance by its US counterpart (AORN), the AnsellCares(R) educational courses have now also received confirmation of acceptance by the European Operating Room Nurses Association. Focusing on infection control, allergy prevention, barrier protection and nursing procedures, the AnsellCares(R) courses perfectly link into the requirements of continued education for healthcare workers around the world. The Ansell educational courses are actually the first courses offered under the newly launched EORNA Accreditation Council for Education (ACE), and will be made accessible via a web-based portal under the EORNA Academy header.
The AnsellCares(R) self-study courses will initially be made available via the EORNA website. EORNA members will be offered logging in to EORNA Academy section of the website, and make their choice on the "offering" page. AnsellCares course content can then be accessed and downloaded. Tests will taken online, delivering final results and accreditation points through a EORNA ACE certificate.
"We are pleased to further extend our support to healthcare workers in Europe, by offering web-based educational courses," says Irini Antoniadou, President of EORNA. "At EORNA, we wholeheartedly back the high quality and thoroughness of AnsellCares courses. They effectively package best practice for nursing professionals," she continues.
AnsellCares(R) educational programmes have been approv
See RNA? http://www.bio-medicine.org/biology-technology-1/Researchers-develop-new-way-to-see-single-RNA-molecules-inside-living-cells-11415-1/
Biomedical engineers have developed a new type of probe that allows them to visualize single ribonucleic acid (RNA) molecules within live cells more easily than existing methods. The tool will help scientists learn more about how RNA operates within living cells.
Techniques scientists currently use to image these transporters of genetic information within cells have several drawbacks, including the need for synthetic RNA or a large number of fluorescent molecules. The fluorescent probes developed at the Georgia Institute of Technology circumvent these issues.
"The probes we designed shine bright, are small and easy to assemble, bind rapidly to their targets, and can be imaged for hours. These characteristics make them a great choice for studying the movement and location of RNA inside a single cell and the interaction between RNA and binding proteins," said Philip Santangelo, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.
Details of the probe production process and RNA imaging strategy were published online in the journal Nature Methods on April 6. In addition to Santangelo, Georgia Tech graduate student Aaron Lifland, Emory University associate professor Gary Bassell and Vanderbilt University professor James Crowe Jr. also contributed to this research. This research was funded by new faculty support from Georgia Tech.
In the study, the probes produced by attaching a few small fluorescent molecules called fluorophores to a modified nucleic acid sequence and combining the sequences with a protein exhibited single-molecule sensitivity and allowed the researchers to target and follow native RNA and non-engineered viral RNA in living cells.
"The great thing about these probes is that they recognize RNA sequences and bind to them using the same base pairing most people are familiar with in regards to DNA," explained Santangelo. "By addin'/>"/>
Contact: Abby Vogelavogel@gatech.edu404-385-3364Georgia Institute of Technology Research NewsSource:Eurekalert
http://www.themarketguardian.com/2009/04/congressional-watchdog-to-drop-a-bombshell-on-the-us-financial-industry/
http://bit.ly/idPt0
RT MarketGuardianCongressional Watchdog to Drop a Bombshell on the US Financial Industry: “set to call for shareholders in.. http://tinyurl.com/cr7ns8
http://bit.ly/iehnq
pete4docSqueeze on US med Doctors has to involve updates on CME also with e-med and dim reimbursements Here is how nurses do it http://bit.ly/iehnq less than 5 seconds ago
pete4dochttp://bit.ly/tjm7 For all the biologics that are going anywhere and whyless than 5 seconds ago from web
visualization example: http://tinyurl.com/d8yr3t it mentions twitter too (via @canuckflack)
http://blog.searchenginewatch.com/090407-140506 - page view increase with spokesperson
http://bit.ly/UFDx3
http://www.itbusinessedge.com/cm/blogs/weinschenk/the-status-of-electronic-health-care-upgraded-to-probable/?cs=31655
medical electronic care
10 signs of needing a life http://www.minervity.com/?p=2392
RT franchiselookup . The name speaks growth
Opportunity for SL http://www.bio-medicine.org/biology-technology-1/Ansell-Healthcare-Espresses-Firm-Commitment-to-Support-Continued-Education-of-Healthcare-Professionals-Worldwide-11417-1/
http://bit.ly/iehnq
BRUSSELS, April 7 /PRNewswire/ --
- European Operating Room Nurses Association (EORNA) to Confirm AnsellCares(R), the Ansell Global Healthcare Educational Program, Accepted for Accreditation
Earlier today, Ansell Healthcare, the global leader in healthcare barrier protective solutions, has announced it has taken a further step in supporting the global healthcare professionals community in the area of continued education.
After receiving earlier confirmation of acceptance by its US counterpart (AORN), the AnsellCares(R) educational courses have now also received confirmation of acceptance by the European Operating Room Nurses Association. Focusing on infection control, allergy prevention, barrier protection and nursing procedures, the AnsellCares(R) courses perfectly link into the requirements of continued education for healthcare workers around the world. The Ansell educational courses are actually the first courses offered under the newly launched EORNA Accreditation Council for Education (ACE), and will be made accessible via a web-based portal under the EORNA Academy header.
The AnsellCares(R) self-study courses will initially be made available via the EORNA website. EORNA members will be offered logging in to EORNA Academy section of the website, and make their choice on the "offering" page. AnsellCares course content can then be accessed and downloaded. Tests will taken online, delivering final results and accreditation points through a EORNA ACE certificate.
"We are pleased to further extend our support to healthcare workers in Europe, by offering web-based educational courses," says Irini Antoniadou, President of EORNA. "At EORNA, we wholeheartedly back the high quality and thoroughness of AnsellCares courses. They effectively package best practice for nursing professionals," she continues.
AnsellCares(R) educational programmes have been approv
See RNA? http://www.bio-medicine.org/biology-technology-1/Researchers-develop-new-way-to-see-single-RNA-molecules-inside-living-cells-11415-1/
Biomedical engineers have developed a new type of probe that allows them to visualize single ribonucleic acid (RNA) molecules within live cells more easily than existing methods. The tool will help scientists learn more about how RNA operates within living cells.
Techniques scientists currently use to image these transporters of genetic information within cells have several drawbacks, including the need for synthetic RNA or a large number of fluorescent molecules. The fluorescent probes developed at the Georgia Institute of Technology circumvent these issues.
"The probes we designed shine bright, are small and easy to assemble, bind rapidly to their targets, and can be imaged for hours. These characteristics make them a great choice for studying the movement and location of RNA inside a single cell and the interaction between RNA and binding proteins," said Philip Santangelo, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.
Details of the probe production process and RNA imaging strategy were published online in the journal Nature Methods on April 6. In addition to Santangelo, Georgia Tech graduate student Aaron Lifland, Emory University associate professor Gary Bassell and Vanderbilt University professor James Crowe Jr. also contributed to this research. This research was funded by new faculty support from Georgia Tech.
In the study, the probes produced by attaching a few small fluorescent molecules called fluorophores to a modified nucleic acid sequence and combining the sequences with a protein exhibited single-molecule sensitivity and allowed the researchers to target and follow native RNA and non-engineered viral RNA in living cells.
"The great thing about these probes is that they recognize RNA sequences and bind to them using the same base pairing most people are familiar with in regards to DNA," explained Santangelo. "By addin'/>"/>
Contact: Abby Vogelavogel@gatech.edu404-385-3364Georgia Institute of Technology Research NewsSource:Eurekalert
http://www.themarketguardian.com/2009/04/congressional-watchdog-to-drop-a-bombshell-on-the-us-financial-industry/
http://bit.ly/idPt0
RT MarketGuardianCongressional Watchdog to Drop a Bombshell on the US Financial Industry: “set to call for shareholders in.. http://tinyurl.com/cr7ns8
http://bit.ly/iehnq
pete4docSqueeze on US med Doctors has to involve updates on CME also with e-med and dim reimbursements Here is how nurses do it http://bit.ly/iehnq less than 5 seconds ago
pete4dochttp://bit.ly/tjm7 For all the biologics that are going anywhere and whyless than 5 seconds ago from web
http://mashable.com/2009/04/05/compare-the-meerkat/
car ins
letter to web company
Howard R,
Thank you for your summary.
Did this letter received give the company the right to include his information under my account number? There is no partnership I have made attempts to form partnerships with him, but he has been evasive. There is an agreement for a small percentage to be paid after costs of profit on our next offering. This does not constitute a partnership.
This data is so tied up that I have yet to see my data and I am still not able to add to it. The communication between you and me and betweeen you and him has led to the data being zipped. If there was a partnership I would have had the password, user name and the , and the account last 4 numbers required for your "authentication process" . There would never have been an expriation. There would not have been a necessity to zip the data and waste time arguing about whether the data existed and who wrote it. Your priority allegiance to him was not warranted especially after I "authenticated" things with the Way Back data in the Archives.
There was a valuable contract lost which I am still in the process of trying to retrieve
which was the direct result of this fiasco. This is where he could have collected monies
but due to his practice of dissappering we lost. Now I am still trying to unzip something that took years to build, based on promises. All is not lost, but there have been costs that have occurred. Who is the executive of your company that deals with these matters over you and over him or her. I need to know their name if nothing else
car ins
letter to web company
Howard R,
Thank you for your summary.
Did this letter received give the company the right to include his information under my account number? There is no partnership I have made attempts to form partnerships with him, but he has been evasive. There is an agreement for a small percentage to be paid after costs of profit on our next offering. This does not constitute a partnership.
This data is so tied up that I have yet to see my data and I am still not able to add to it. The communication between you and me and betweeen you and him has led to the data being zipped. If there was a partnership I would have had the password, user name and the , and the account last 4 numbers required for your "authentication process" . There would never have been an expriation. There would not have been a necessity to zip the data and waste time arguing about whether the data existed and who wrote it. Your priority allegiance to him was not warranted especially after I "authenticated" things with the Way Back data in the Archives.
There was a valuable contract lost which I am still in the process of trying to retrieve
which was the direct result of this fiasco. This is where he could have collected monies
but due to his practice of dissappering we lost. Now I am still trying to unzip something that took years to build, based on promises. All is not lost, but there have been costs that have occurred. Who is the executive of your company that deals with these matters over you and over him or her. I need to know their name if nothing else
Sunday, April 5, 2009
Kevin Roberts (aka Marco Polo)
From Kevin Roberts world Traveler
Ko Samui, Thailand. An island in Thailand. I think Ko means island, like Cay. Samui Island. The Garden of Eden couldn't have been much more lush than this one. I had a great day here. My goal today was to take some pictures, get wet, and not spend much money. I accomplished all three plus I had a lot of fun. We tendered in here. First time I've been on a tender boat since Dubrovnik, Croatia right before I signed off of Journey. I hadn't even thought about the fact that we haven't had to tender. But this is more like what I'm used to in terms of cruising. It is a tropical paradise. Like I said, I'm not much of a beach person anymore. I would have loved to go diving here. I saw lots of dive shops. But I found something even more exciting than that. When I stepped off he end of the pier, I saw a scooter rental stand. The guy said it cost 150 Baht for all day. I pulled out a five dollar bill before he could change his mind. :) And didn't ask for change! Nice little motor scooter. $2 worth of gas, and I was off. Then I realized that, wouldn't you know it, the first place I've rented a scooter is in a country that drives on the left side of the road! (Well, I guess we had to fight a war to be able to drive on the right side of the road). I'll be honest with you, it probably was not a good idea. But I haven't been on a bike in a while and I needed it. I figure it was quite a bit more dangerous than hang gliding. So I had to be careful. Even though it is a fairly small island (I'd say similar to Cozumel), in any of the larger towns, there was quite a bit of traffic. And although there was a dedicated scooter lane on the left, they darted in and out of traffic everywhere. And I couldn't get used to people passing me on the right. I had to train myself to constantly watch my mirrors. Riding the scooter was not difficult once I got used to the gears being backwards from what I'm accustomed to. Instead of one-down and four-up like motorcycles, it was four-down. I did screech the tires a few times up-shifting when I should have been down-shifting. But it was automatic so I didn't have to use a clutch. And it was pretty idiot-proof. You could start it and run in any gear as long as you didn't try to accelerate too fast. Now on top of all this, add to the mix that everywhere you turn, there is something beautiful to take a picture of. I even turned off main road several times and found smaller pieces of paradise. And people living there farming and doing their thing. I finally decided I had better quit taking pictures and concentrate on riding that scooter. Eventually, I found out that the best way to make time was to stay out of the scooter lane. Most people ride them really slow and turn on and off the road. If you stay to the right with the cars, and keep going as fast as they are, you can make some time. So I scouted a few places on the map to stop and see, let me hair down, and zoomed off. :) I drove a lot faster but I figure it was safer as I stayed away from the other scooters and the cars knew exactly where I was. And it was more fun than any one man ought to be allowed to have! I got a picture of the big Buddha. They built one right by the water here. I first saw it when I stopped to photograph the beach at a little park. I saw this big gold-looking thing on the horizon and realized that it had to be the Buddha. I had heard about it. I also found a really nice waterfall. That was right next to the eco park. Most of the island is a big nature preserve but there was a crew tour to this park and it offered an elephant trek, playing with the monkeys, etc. I really want to ride an elephant but they wanted too much money. Anyhow, I had a blast today. I almost feel sorry for the rest of humanity today. Almost. :) And I topped it off with a Thai coffee. I never drink iced coffee. But it turned out to be one of the most refreshing drinks ever. Oh yeah, I did get wet. For a while, it rained. Hard! Which added to the excitement of riding the scooter. But I knew it wouldn't last long and it didn't. It rains a little every day in the tropics. That's why it is so lush. Anyway, I missed enough pictures and activities that I've got a good excuse to come back. If I ever get a Round Tuit. Might just stay the next time. Ciao....KR
Ko Samui, Thailand. An island in Thailand. I think Ko means island, like Cay. Samui Island. The Garden of Eden couldn't have been much more lush than this one. I had a great day here. My goal today was to take some pictures, get wet, and not spend much money. I accomplished all three plus I had a lot of fun. We tendered in here. First time I've been on a tender boat since Dubrovnik, Croatia right before I signed off of Journey. I hadn't even thought about the fact that we haven't had to tender. But this is more like what I'm used to in terms of cruising. It is a tropical paradise. Like I said, I'm not much of a beach person anymore. I would have loved to go diving here. I saw lots of dive shops. But I found something even more exciting than that. When I stepped off he end of the pier, I saw a scooter rental stand. The guy said it cost 150 Baht for all day. I pulled out a five dollar bill before he could change his mind. :) And didn't ask for change! Nice little motor scooter. $2 worth of gas, and I was off. Then I realized that, wouldn't you know it, the first place I've rented a scooter is in a country that drives on the left side of the road! (Well, I guess we had to fight a war to be able to drive on the right side of the road). I'll be honest with you, it probably was not a good idea. But I haven't been on a bike in a while and I needed it. I figure it was quite a bit more dangerous than hang gliding. So I had to be careful. Even though it is a fairly small island (I'd say similar to Cozumel), in any of the larger towns, there was quite a bit of traffic. And although there was a dedicated scooter lane on the left, they darted in and out of traffic everywhere. And I couldn't get used to people passing me on the right. I had to train myself to constantly watch my mirrors. Riding the scooter was not difficult once I got used to the gears being backwards from what I'm accustomed to. Instead of one-down and four-up like motorcycles, it was four-down. I did screech the tires a few times up-shifting when I should have been down-shifting. But it was automatic so I didn't have to use a clutch. And it was pretty idiot-proof. You could start it and run in any gear as long as you didn't try to accelerate too fast. Now on top of all this, add to the mix that everywhere you turn, there is something beautiful to take a picture of. I even turned off main road several times and found smaller pieces of paradise. And people living there farming and doing their thing. I finally decided I had better quit taking pictures and concentrate on riding that scooter. Eventually, I found out that the best way to make time was to stay out of the scooter lane. Most people ride them really slow and turn on and off the road. If you stay to the right with the cars, and keep going as fast as they are, you can make some time. So I scouted a few places on the map to stop and see, let me hair down, and zoomed off. :) I drove a lot faster but I figure it was safer as I stayed away from the other scooters and the cars knew exactly where I was. And it was more fun than any one man ought to be allowed to have! I got a picture of the big Buddha. They built one right by the water here. I first saw it when I stopped to photograph the beach at a little park. I saw this big gold-looking thing on the horizon and realized that it had to be the Buddha. I had heard about it. I also found a really nice waterfall. That was right next to the eco park. Most of the island is a big nature preserve but there was a crew tour to this park and it offered an elephant trek, playing with the monkeys, etc. I really want to ride an elephant but they wanted too much money. Anyhow, I had a blast today. I almost feel sorry for the rest of humanity today. Almost. :) And I topped it off with a Thai coffee. I never drink iced coffee. But it turned out to be one of the most refreshing drinks ever. Oh yeah, I did get wet. For a while, it rained. Hard! Which added to the excitement of riding the scooter. But I knew it wouldn't last long and it didn't. It rains a little every day in the tropics. That's why it is so lush. Anyway, I missed enough pictures and activities that I've got a good excuse to come back. If I ever get a Round Tuit. Might just stay the next time. Ciao....KR
I thought I was through!
India times
http://bit.ly/Pivsb
http://bit.ly/DOvfc
Software stim
http://bit.ly/jNsv
For Todays Daily Bread
http://bit.ly/196omj
Web Hosting
http://bit.ly/12m80A
Chinese Social Networks
http://bit.ly/4U3Gk
Brain Activity: And in Houston!!!
http://bit.ly/4zm26k
pic of Pic -ER 12seconds.tv (beta)
http://bit.ly/IM8Y6
Growths and Cancer and Abnormality Cures
http://bit.ly/mSjiM
12 sec Videos
http://bit.ly/OShwH
Stanford Computer Science
http://bit.ly/bhLy
PDF 4u
http://bit.ly/dQHsc
Target and Its Management
http://bit.ly/c8edm
Legalise with Twitter
http://bit.ly/ZJuIA
http://bit.ly/Pivsb
http://bit.ly/DOvfc
Software stim
http://bit.ly/jNsv
For Todays Daily Bread
http://bit.ly/196omj
Web Hosting
http://bit.ly/12m80A
Chinese Social Networks
http://bit.ly/4U3Gk
Brain Activity: And in Houston!!!
http://bit.ly/4zm26k
pic of Pic -ER 12seconds.tv (beta)
http://bit.ly/IM8Y6
Growths and Cancer and Abnormality Cures
http://bit.ly/mSjiM
12 sec Videos
http://bit.ly/OShwH
Stanford Computer Science
http://bit.ly/bhLy
PDF 4u
http://bit.ly/dQHsc
Target and Its Management
http://bit.ly/c8edm
Legalise with Twitter
http://bit.ly/ZJuIA
Just a smidgen of the best
Animated avitars http://forums.macnn.com/82/applications/195029/how-do-you-create-animated-avitars/
http://www.tmzhosting.com/ -Cheap hosting
http://www.nytimes.com/2009/04/06/technology/business-computing/06blue.html?_r=1&hp
JRStratfordIBM Withdraws $7 Billion Offer for Sun Microsystems. http://ping.fm/emr9S Please RT
The breakdown in the talks, said the second person close to the negotiations, came over the shifting balance of price and conditions for the deal.
For example, I.B.M. scrutinized the "change of control" contracts with Sun executives, senior engineers and managers. I.B.M. felt that the payments to senior employees were higher and extended more broadly across the company than it had anticipated. I.B.M. pointed to the change of control contracts as one reason it was reducing its offer price.
http://www.theatlantic.com/doc/200905/imf-advice
@ http://twitter.com/aein
http://tinyurl.com/66nt79 cuuuteee
http://www.tmzhosting.com/
http://www.tmzhosting.com/ -Cheap hosting
http://www.nytimes.com/2009/04/06/technology/business-computing/06blue.html?_r=1&hp
JRStratfordIBM Withdraws $7 Billion Offer for Sun Microsystems. http://ping.fm/emr9S Please RT
The breakdown in the talks, said the second person close to the negotiations, came over the shifting balance of price and conditions for the deal.
For example, I.B.M. scrutinized the "change of control" contracts with Sun executives, senior engineers and managers. I.B.M. felt that the payments to senior employees were higher and extended more broadly across the company than it had anticipated. I.B.M. pointed to the change of control contracts as one reason it was reducing its offer price.
http://www.theatlantic.com/doc/200905/imf-advice
@ http://twitter.com/aein
http://tinyurl.com/66nt79 cuuuteee
http://www.tmzhosting.com/
Thursday, April 2, 2009
4-2-9
http://cs.stanford.edu/
computer science school necessity
seminar
Algorithms Seminar - Title: EE 388 Modern Coding Theory - Instructor: Prof. A. Montanari
WhenThu, April 2, 12:30pm – 1:30pm
DescriptionClass Times and Locations * Tuesdays and Thursdays, 12:35-02:05 PM in Room: Gates 380-380D Course Description Tools for analysis and optimization of iterative coding systems. LDPC, turbo and RA codes. Optimized ensembles, message passing algorithms, density evolution, and analytic techniques. References The course is mainly based on T. Richardson and R. Urbanke, Modern Coding Theory Additional references are M. Mezard and A. Montanari, Information, Physics, and Computation R. G. Gallager, Low Density Parity Check Codes Prerequisites The prerequisite mentioned in the bulletin is EE376A (Information Theory.) If you did not take EE376A, this is not a problem. On the other hand, it is important to know some basic probability (say, enough probability for understanding a proof of the central limit theorem.) Webpage: http://www.stanford.edu/class/ee388/
Symbolic Systems Forum - Margaret Boden, Univ. of Sussex, "Creativity and Computers" - The Annual Symbolic Systems Distinguished Speaker Lecture
WhenThu, April 2, 4pm – 5pm
WhereBuilding 380, Room 380C (Math Corner)
DescriptionAlso speaking 4/3 , 12:00 noon "Turing and Artificial Life" The Wasow Scholar Lunch Seminar ABSTRACT: "Creativity and Computers" (4/2, SSP Forum, 4:15 pm): Creativity is the ability to come up with ideas that are new, surprising, and valuable. It doesn't happen by magic, but involves psychological processes that can be described by science. There are three ways of generating creative ideas: combinational, exploratory, and transformational. Each of these can be modelled, at least up to a point, in computers. Surprisingly, perhaps, combinational creativity is the least easy to model. Also surprisingly, the main problem in modelling transformational creativity is not generating the transformations, but evaluating the results. Computational concepts can help us to understand how creativity is possible. But no scientific psychology (with or without neuroscience) could predict every new idea--nor even explain every one in detail, post hoc. SPEAKER: Margaret Boden, Research Professor of Cognitive Science Department of Informatics, University of Sussex Thomas A. Wasow Visiting Scholar, Symbolic Systems Program symsys-events mailing list symsys-events@lists.stanford.edu
https://mailman.stanford.edu/mailman/listinfo/symsys-events
The Wasow Scholar Lunch Seminar - Symbolic Systems - Margaret Boden, Univ. of Sussex, "Turing and Artificial Life"
WhenFri, April 3, 12pm – 1pm
WhereBuilding 380, Room 380C (Math Corner)
DescriptionAlso speaking 4/2 , 4:15 PM "Creativity and Computers" - The Annual Symbolic Systems Distinguished Speaker Lecture, Symbolic Systems Forum "Turing and Artificial Life" Margaret Boden, Univ. of Sussex ABSTRACT "Turing and Artificial Life" (4/3, 12 noon): In his 1950 paper in MIND, in which he introduced the Turing Test, Alan Turing mentioned two ideas that would eventually be hugely important in A-Life. These were evolutionary computing, and the fourfold classification of computational systems that was later clarified by Stephen Wolfram. However, he merely remarked on these in passing, while setting out his (hugely prescient) manifesto for a future AI. With respect to A-Life, his last published paper, on "The Chemical Basis of Morphogenesis" (1952) was much more important. He showed there how a homogeneous source, such as an undifferentiated ovum, could spontaneously self-organize, producing new forms of order where none existed before. This could happen by way of familiar physical laws, or "reaction-diffusion systems", wherein chemicals diffuse and inter-react so as to generate patterns of concentration that could act as the basis of anatomical/morphological structures (e.g. stripes and dappling, or petals/tentacles/segments). Over thirty years later, computer power (and computer graphics) had advanced enough for Turing's equations to be explored beyond the very simple examples that he could deal with in the early 1950s, and for generating novel patterns out of pre-existing patterns (as opposed to homogeneity). SPEAKER: Margaret Boden, Research Professor of Cognitive Science Department of Informatics, University of Sussex Thomas A. Wasow Visiting Scholar, Symbolic Systems Program symsys-events mailing list symsys-events@lists.stanford.edu https://mailman.stanford.edu/mailman/listinfo/symsys-events
600pm
Sun Microsystems - MySQL Talk
WhenThu, April 16, 6pm – 7pm
WherePackard Building, room 101 escriptionMeet, Greet, and Eat What the MySQL is this anyway? An introduction to a five letter phenomenon and why you should care. WHERE: Stanford, Packard 101 WHEN: Thursday, April 16 - 6-7pm WHO: Colin Charles, Sun/MySQL Community Relations Manager of APAC WHY: Learn about Sun / MySQL / OpenSource Free Food and Giveaways Provided Seating is Limited! Colin Charles is the Community Relations Manager, APAC at MySQL/The Database Group, Sun Microsystems. He lives in Kuala Lumpur, Malaysia (after having moved from Melbourne, Australia in April 2008) and has been with MySQL since 2005. Before joining MySQL, he worked actively on the Fedora and OpenOffice.org projects. He currently spends a lot of his time making community-based projects happy using the MySQL database. His main role is to deal with distributions shipping MySQL, but he’s also co-ordinated the MySQL participation in the Google Summer of Code. He’s spoken at many conferences – linux.conf.au, The MySQL Conference & Expo, foss.in
Stanford iphone ap course free http://itunes.stanford.edu/ For videos slides
http://news.stanford.edu/news/2009/april1/free-iphone-software-development-course-apple-040109.html
http://bit.ly/16uH3c
http://www.getthebar.com/help_videos2.php
http://www.merchantcircle.com/business/Wheeler.Avenue.Baptist.Church.713-748-0176
http://bit.ly/xM7bX
Update Your Picture
Positive That came out
http://www.historicaerials.com/
http://bit.ly/H2bx
My effort to stop
historicaerials.com.
http://www.gregthatcher.com/Financial/Default.aspx?action=browseByState&arg=TX
bank routing numbers
AERIAL VIEW of sportsman park
http://bit.ly/QBrGJ
code sportsman part st.louis
http://bit.ly/OGJPp
computer science school necessity
seminar
Algorithms Seminar - Title: EE 388 Modern Coding Theory - Instructor: Prof. A. Montanari
WhenThu, April 2, 12:30pm – 1:30pm
DescriptionClass Times and Locations * Tuesdays and Thursdays, 12:35-02:05 PM in Room: Gates 380-380D Course Description Tools for analysis and optimization of iterative coding systems. LDPC, turbo and RA codes. Optimized ensembles, message passing algorithms, density evolution, and analytic techniques. References The course is mainly based on T. Richardson and R. Urbanke, Modern Coding Theory Additional references are M. Mezard and A. Montanari, Information, Physics, and Computation R. G. Gallager, Low Density Parity Check Codes Prerequisites The prerequisite mentioned in the bulletin is EE376A (Information Theory.) If you did not take EE376A, this is not a problem. On the other hand, it is important to know some basic probability (say, enough probability for understanding a proof of the central limit theorem.) Webpage: http://www.stanford.edu/class/ee388/
Symbolic Systems Forum - Margaret Boden, Univ. of Sussex, "Creativity and Computers" - The Annual Symbolic Systems Distinguished Speaker Lecture
WhenThu, April 2, 4pm – 5pm
WhereBuilding 380, Room 380C (Math Corner)
DescriptionAlso speaking 4/3 , 12:00 noon "Turing and Artificial Life" The Wasow Scholar Lunch Seminar ABSTRACT: "Creativity and Computers" (4/2, SSP Forum, 4:15 pm): Creativity is the ability to come up with ideas that are new, surprising, and valuable. It doesn't happen by magic, but involves psychological processes that can be described by science. There are three ways of generating creative ideas: combinational, exploratory, and transformational. Each of these can be modelled, at least up to a point, in computers. Surprisingly, perhaps, combinational creativity is the least easy to model. Also surprisingly, the main problem in modelling transformational creativity is not generating the transformations, but evaluating the results. Computational concepts can help us to understand how creativity is possible. But no scientific psychology (with or without neuroscience) could predict every new idea--nor even explain every one in detail, post hoc. SPEAKER: Margaret Boden, Research Professor of Cognitive Science Department of Informatics, University of Sussex Thomas A. Wasow Visiting Scholar, Symbolic Systems Program symsys-events mailing list symsys-events@lists.stanford.edu
https://mailman.stanford.edu/mailman/listinfo/symsys-events
The Wasow Scholar Lunch Seminar - Symbolic Systems - Margaret Boden, Univ. of Sussex, "Turing and Artificial Life"
WhenFri, April 3, 12pm – 1pm
WhereBuilding 380, Room 380C (Math Corner)
DescriptionAlso speaking 4/2 , 4:15 PM "Creativity and Computers" - The Annual Symbolic Systems Distinguished Speaker Lecture, Symbolic Systems Forum "Turing and Artificial Life" Margaret Boden, Univ. of Sussex ABSTRACT "Turing and Artificial Life" (4/3, 12 noon): In his 1950 paper in MIND, in which he introduced the Turing Test, Alan Turing mentioned two ideas that would eventually be hugely important in A-Life. These were evolutionary computing, and the fourfold classification of computational systems that was later clarified by Stephen Wolfram. However, he merely remarked on these in passing, while setting out his (hugely prescient) manifesto for a future AI. With respect to A-Life, his last published paper, on "The Chemical Basis of Morphogenesis" (1952) was much more important. He showed there how a homogeneous source, such as an undifferentiated ovum, could spontaneously self-organize, producing new forms of order where none existed before. This could happen by way of familiar physical laws, or "reaction-diffusion systems", wherein chemicals diffuse and inter-react so as to generate patterns of concentration that could act as the basis of anatomical/morphological structures (e.g. stripes and dappling, or petals/tentacles/segments). Over thirty years later, computer power (and computer graphics) had advanced enough for Turing's equations to be explored beyond the very simple examples that he could deal with in the early 1950s, and for generating novel patterns out of pre-existing patterns (as opposed to homogeneity). SPEAKER: Margaret Boden, Research Professor of Cognitive Science Department of Informatics, University of Sussex Thomas A. Wasow Visiting Scholar, Symbolic Systems Program symsys-events mailing list symsys-events@lists.stanford.edu https://mailman.stanford.edu/mailman/listinfo/symsys-events
600pm
Sun Microsystems - MySQL Talk
WhenThu, April 16, 6pm – 7pm
WherePackard Building, room 101 escriptionMeet, Greet, and Eat What the MySQL is this anyway? An introduction to a five letter phenomenon and why you should care. WHERE: Stanford, Packard 101 WHEN: Thursday, April 16 - 6-7pm WHO: Colin Charles, Sun/MySQL Community Relations Manager of APAC WHY: Learn about Sun / MySQL / OpenSource Free Food and Giveaways Provided Seating is Limited! Colin Charles is the Community Relations Manager, APAC at MySQL/The Database Group, Sun Microsystems. He lives in Kuala Lumpur, Malaysia (after having moved from Melbourne, Australia in April 2008) and has been with MySQL since 2005. Before joining MySQL, he worked actively on the Fedora and OpenOffice.org projects. He currently spends a lot of his time making community-based projects happy using the MySQL database. His main role is to deal with distributions shipping MySQL, but he’s also co-ordinated the MySQL participation in the Google Summer of Code. He’s spoken at many conferences – linux.conf.au, The MySQL Conference & Expo, foss.in
Stanford iphone ap course free http://itunes.stanford.edu/ For videos slides
http://news.stanford.edu/news/2009/april1/free-iphone-software-development-course-apple-040109.html
http://bit.ly/16uH3c
http://www.getthebar.com/help_videos2.php
http://www.merchantcircle.com/business/Wheeler.Avenue.Baptist.Church.713-748-0176
http://bit.ly/xM7bX
Update Your Picture
Positive That came out
http://www.historicaerials.com/
http://bit.ly/H2bx
My effort to stop
historicaerials.com.
http://www.gregthatcher.com/Financial/Default.aspx?action=browseByState&arg=TX
bank routing numbers
AERIAL VIEW of sportsman park
http://bit.ly/QBrGJ
code sportsman part st.louis
http://bit.ly/OGJPp
Subscribe to:
Posts (Atom)